Pharmaceucticals

‘Rushed’ Drug Development that Aims to Refill Pharma Firms’ Pipelines Is Less Likely to Succeed Because of Inter-organizational Friction

When a large pharmaceutical company experiences a drug trial failure and then tries to refill its pipeline by licensing a product created by another firm, such a “rushed innovation” is less likely to bring a product to market than one developed under normal, less hurried conditions. That’s because the hastily drawn licensing agreement between the two organizations leads to friction that drags development work to a halt.